MedTrace Logo

ELITE: Early Versus Late Intervention Trial With Estradiol

NCT00114517 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 643

Last updated 2023-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.

Conditions

Interventions

DRUG

17B-estradiol

Oral 17B-estradiol 1 mg daily

OTHER

Placebo

Matching oral 17B-estradiol placebo daily

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Howard N. Hodis, M.D. · Atherosclerosis Research Unit, University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2013-02-12
Completion
2013-03-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00114517 on ClinicalTrials.gov